Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Product

cisplatin

Aliases
CACP, CDDP, Chemotherapy, Cis-diaminedichloroplatinum Cis-diaminedichloroplatinum (II) (11 other aliases)

65 clinical trials

82 indications

Indication
Lung Cancer
Indication
Cervical Cancer
Indication
lung cancer
Indication
Non-squamous
Indication
Non Small Cell
Indication
Colorectal Cancer
Indication
cancer
Indication
Non-Small Cell Lung
Indication
Pancreatic Cancer
Indication
Squamous Cell Carcinoma of Head and Neck
Indication
Esophageal Squamous Cell Carcinoma
Indication
Gastroesophageal Junction Carcinoma
Indication
Esophageal Adenocarcinoma (EAC)
Indication
Breast Neoplasms
Indication
Esophageal squamous cell carcinoma
Indication
Esophageal adenocarcinoma
Indication
Esophageal Cancer
Indication
Ovarian Cancer
Indication
Cutaneous Squamous Cell Carcinoma
Indication
Pancreatic cancer
Indication
Bladder Cancer
Indication
Stomach Neoplasms
Indication
Persistent
Indication
Recurrent
Indication
Solid Tumors
Indication
Transitional Cell
Indication
Urologic Neoplasms
Indication
Renal Pelvis Neoplasms
Indication
Ureteral Neoplasms
Indication
Urethral Neoplasms
Indication
Endometrial Neoplasms
Indication
Human Papillomavirus Infection
Indication
Stage III Squamous Cell Carcinoma of the Oropharynx
Indication
Stage IVA Squamous Cell Carcinoma of the Oropharynx
Indication
Stage IVB Squamous Cell Carcinoma of the Oropharynx
Indication
Sarcoma
Indication
Head and Neck Cancer
Indication
Recurrent Non-small Cell Lung Cancer
Indication
Stage IIB Non-small Cell Lung Cancer
Indication
Stage IIIA Non-small Cell Lung Cancer
Indication
Head and Neck Squamous Cell Carcinoma
Indication
Triple Negative Breast Cancer
Indication
lymphoma
Indication
Neutropenia
Indication
Nasopharyngeal Carcinoma
Indication
Nutritional Support
Indication
Cancer
Indication
Endometrial Cancer
Indication
Brain and Central Nervous System Tumors
Indication
Neuroblastoma
Indication
Germ Cell Tumor
Indication
Teratoma
Indication
Testicular Germ Cell Tumor
Indication
Triple-Negative Breast Cancer
Indication
Breast Cancer
Indication
Precancerous Condition
Indication
Choriocarcinoma
Indication
Germinoma
Indication
Mixed Germ Cell Tumor
Indication
yolk sac tumor
Indication
Malignant Germ Cell Neoplasm
Indication
Extragonadal Seminoma
Indication
Nonseminomatous Germ Cell Tumor
Indication
Testicular seminoma
Indication
Fallopian tube cancer
Indication
Metastatic Cancer
Indication
Peritoneal Cavity Cancer
Indication
Nasopharyngeal Neoplasms
Indication
Nasopharyngeal Diseases
Indication
Head and Neck Neoplasm
Indication
solid tumor
Indication
Protocol Specific
Indication
urethral cancer
Indication
Esophageal cancer
Indication
Stomach Cancer
Indication
Transitional Cell Cancer of the Renal Pelvis and Ureter
Indication
Melanoma
Indication
Liver Cancer
Indication
Small Cell Lung Cancer
Indication
Cervical cancer
Indication
Anal Cancer
Indication
NSCLC
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Phase III Study Evaluating the Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab as First Line Therapy for Locally Advanced or Metastatic Non-squamous and Squamous Non-small Cell Lung Cancer Subjects (CANOPY-1)
Status: Active (not recruiting), Estimated PCD: 2021-08-09
Clinical trial
A Phase 1/2 Study to Evaluate the Safety, Tolerability, Preliminary Efficacy of KRC-01 Intratumoral Injection Combined With Radiotherapy in Patients With Locally Advanced Cervical Cancer
Status: Not yet recruiting, Estimated PCD: 2027-01-30
Clinical trial
Beamion LUNG-2: A Phase III, Open-label, Randomized, Active-controlled, Multi-centre Trial Evaluating Orally Administered BI 1810631 Compared With Standard of Care as First-line Treatment in Patients With Unresectable, Locally Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer Harbouring HER2 Tyrosine Kinase Domain Mutations
Status: Recruiting, Estimated PCD: 2027-03-31
Clinical trial
A Randomized, Double-Blind, Phase 3 Study of Pemetrexed + Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in TKI-resistant EGFR-mutated Tumors in Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) Participants (KEYNOTE-789)
Status: Completed, Estimated PCD: 2023-01-17
Clinical trial
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors
Status: Recruiting, Estimated PCD: 2025-04-30
Clinical trial
A Randomized, Double-blind, Placebo-controlled Phase 3 Trial of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Receiving Concurrent Definitive Chemoradiotherapy (KEYNOTE 975)
Status: Active (not recruiting), Estimated PCD: 2027-02-01
Clinical trial
A Phase 1 Study of SGN-B6A in Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2026-11-30
Clinical trial
An Open-label, Randomized, Controlled Phase 3 Study of Disitamab Vedotin in Combination With Pembrolizumab Versus Chemotherapy in Subjects With Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma That Expresses HER2 (IHC 1+ and Greater)
Status: Recruiting, Estimated PCD: 2026-06-30
Clinical trial
PD-1 Antibody SHR-1210 Combined With Paclitaxel and Cisplatin Versus Placebo Combined With Paclitaxel and Cisplatin as First-line Therapy for Advanced Esophageal Cancer: a Randomized, Double-blinded, Controlled, Multi-center Phase III Trial
Status: Completed, Estimated PCD: 2020-10-30
Clinical trial
A Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate GLS-010 Plus Platinum-containing Chemotherapy With or Without Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer
Status: Not yet recruiting, Estimated PCD: 2025-05-01
Clinical trial
A Phase I Dose Escalation Study Evaluating MK-1775 in Both Monotherapy and in Combination With Either Gemcitabine, Cisplatin, or Carboplatin in Adult Subjects With Advanced Solid Tumors
Status: Completed, Estimated PCD: 2014-01-06
Clinical trial
A Study of Enfortumab Vedotin (ASG-22CE) as Monotherapy or in Combination With Other Anticancer Therapies for the Treatment of Urothelial Cancer
Status: Active (not recruiting), Estimated PCD: 2026-12-31
Clinical trial
A Phase 3 Randomized, Open-label, Active-comparator Controlled Clinical Study of Pembrolizumab Versus Platinum Doublet Chemotherapy in Participants With Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma in the First-line Setting (KEYNOTE-C93/GOG-3064/ENGOT-en15)
Status: Active (not recruiting), Estimated PCD: 2026-07-17
Clinical trial
Phase II Randomized Trial of Transoral Surgical Resection Followed by Low-Dose or Standard-Dose IMRT in Resectable p16+ Locally Advanced Oropharynx Cancer
Status: Active (not recruiting), Estimated PCD: 2020-11-30
Clinical trial
OS2006 : Protocole de Traitement Des ostéosarcomes de l'Enfant, de l'Adolescent et de l'Adulte Comportant
Status: Active (not recruiting), Estimated PCD: 2015-12-01
Clinical trial
Multimodality Management of Head and Neck Cancer: A Phase II Trial of Induction Chemotherapy, Organ Preservation Surgery, and Concurrent Chemoradiotherapy
Status: Active (not recruiting), Estimated PCD: 2017-02-14
Clinical trial
A Randomized Phase II/Phase III Study of Adjuvant Concurrent Radiation and Chemotherapy Versus Radiation Alone in Resected High-Risk Malignant Salivary Gland Tumors
Status: Active (not recruiting), Estimated PCD: 2026-10-31
Clinical trial
A Phase II Trial Combining Hypofractionated Radiation Boost With Conventionally-Fractionated Chemoradiation in Locally Advanced Non-small Cell Lung Cancer Not Suitable for Surgery
Status: Active (not recruiting), Estimated PCD: 2024-07-31
Clinical trial
Comparison of Concomitant Cisplatin Versus Carboplatin and 5-fluorouracil With Radiotherapy for Locally Advanced Head and Neck Squamous Cell Carcinoma
Status: Completed, Estimated PCD: 2017-03-01
Clinical trial
A Phase II Trial of Homologous Recombination Repair Status as a Biomarker of Response in Locally Recurrent/Metastatic Triple Negative Breast Cancer Patients Treated With Concurrent Cisplatin and Radiation Therapy
Status: Completed, Estimated PCD: 2022-12-19
Clinical trial
A Phase II Protocol for Patients With Stage T1 Bladder Cancer to Evaluate Selective Bladder Preserving Treatment by Radiation Therapy Concurrent With Radiosensitizing Chemotherapy Following a Thorough Transurethral Surgical Re-Staging
Status: Completed, Estimated PCD: 2021-03-01
Clinical trial
A Phase II Clinical Study of Penpulimab Combined With Chemotherapy for Neoadjuvant and Adjuvant Therapy in Patients With Resectable Head and Neck Squamous Cell Carcinoma
Status: Recruiting, Estimated PCD: 2024-12-30
Clinical trial
A Randomized, Multicenter, Open-Label Study of Single Dose Filgrastim-SD/01 Versus Daily Filgrastim Following ESHAP Chemotherapy for Non-Hodgkin's Lymphoma
Status: Completed, Estimated PCD: 2001-02-01
Clinical trial
Effect of Oral Nutritional Supplements From the Beginning of Radiotherapy on Body Weight Loss of Patients With Nasopharyngeal Carcinoma and Its Cost-Utility Analysis: A Prospective Multicenter Randomized Controlled Trial
Status: Recruiting, Estimated PCD: 2025-07-01
Clinical trial
A Phase 1 Trial of MK-7684 as Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
Status: Active (not recruiting), Estimated PCD: 2024-08-01
Clinical trial
Randomized Phase III Trial Comparing Concurrent Chemoradiation and Adjuvant Chemotherapy With Pelvic Radiation Alone in High Risk and Advanced Stage Endometrial Carcinoma: PORTEC-3
Status: Active (not recruiting), Estimated PCD: 2018-11-29
Clinical trial
Treatment of Patients With Newly Diagnosed Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Atypical Teratoid Rhabdoid Tumor
Status: Completed, Estimated PCD: 2016-12-01
Clinical trial
Neuroblastoma Protocol 2012: Therapy for Children With Advanced Stage High-Risk Neuroblastoma
Status: Active (not recruiting), Estimated PCD: 2021-10-21
Clinical trial
A Randomized Trial Comparing Induction Gemcitabine and Cisplatin Plus Intensity-modulated Radiotherapy With Concurrent Cisplatin Plus Intensity-modulated Radiotherapy in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma
Status: Active (not recruiting), Estimated PCD: 2022-04-01
Clinical trial
A Risk-Adapted Strategy of the Use of Dose-Dense Chemotherapy in Patients With Poor-Prognosis Disseminated Non-Seminomatous Germ Cell Tumors
Status: Active (not recruiting), Estimated PCD: 2012-03-29
Clinical trial
Open-label Phase 3 Study of MK-7684A (Coformulation of Vibostolimab With Pembrolizumab) in Combination With Concurrent Chemoradiotherapy Followed by MK-7684A Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Unresectable, Locally Advanced, Stage III NSCLC
Status: Recruiting, Estimated PCD: 2028-09-01
Clinical trial
Efficacy and Safety Study of TA(E)C-GP Versus A(E)C-T for the High Risk Triple-negative Breast Cancer Patients Predicted by the Messenger RNA (mRNA)-Long Non-coding RNA (lncRNA) Signature and Validation of the Signature's Efficacy
Status: Active (not recruiting), Estimated PCD: 2023-12-01
Clinical trial
Phase III Trial of Radiotherapy Plus Cetuximab Versus Chemoradiotherapy in HPV-Associated Oropharynx Cancer
Status: , Estimated PCD: 2018-07-12
Clinical trial
A Randomized Phase III Trial Comparing Conventional-Dose Chemotherapy Using Paclitaxel, Ifosfamide, and Cisplatin (TIP) With High-Dose Chemotherapy Using Mobilizing Paclitaxel Plus Ifosfamide Followed by High-Dose Carboplatin and Etoposide (TI-CE) as First Salvage Treatment in Relapsed or Refractory Germ Cell Tumors
Status: Active (not recruiting), Estimated PCD: 2024-06-01
Clinical trial
Phase III Randomized Study of Concurrent Chemotherapy and Pelvic Radiation Therapy With or Without Adjuvant Chemotherapy in High-Risk Patients With Early-Stage Cervical Carcinoma Following Radical Hysterectomy
Status: Active (not recruiting), Estimated PCD: 2023-12-14
Clinical trial
A Phase II Study of Intraperitoneal (IP) Plus Intravenous (IV) Chemotherapy Versus IV Carboplatin Plus Paclitaxel in Patients With Epithelial Ovarian Cancer Optimally Debulked at Surgery Following Neoadjuvant Intravenous Chemotherapy
Status: Completed, Estimated PCD: 2016-03-10
Clinical trial
GP vs PF as Induction Chemotherapy Combined With CCRT for Locoregionally Advanced Nasopharyngeal Carcinoma：a Prospective,Parallel, Randomized, Open Labeled, Multicenter Phase III Clinical Trial
Status: Active (not recruiting), Estimated PCD: 2026-08-31
Clinical trial
Phase II Study of Weekly Docetaxel Together With Weekly Cisplatin in Chemotherapy-Naive Patients With Stage IV or Select Stage IIIB (Malignant Effusion) Non-Small Cell Lung Cancer
Status: Terminated, Estimated PCD: 2010-02-01
Clinical trial
An Exploratory Pilot Study of Nab-paclitaxel Based Induction Chemotherapy Followed by Response-Stratified Locoregional Therapy for Patients With Stage III and IV HPV-Related Oropharyngeal Cancer - the OPTIMA HPV Trial
Status: Active (not recruiting), Estimated PCD: 2019-03-31
Clinical trial
A Phase II Study of Cisplatin and Gemcitabine in Patients With Locally Advanced/Recurrent or Metastatic Malignant Salivary Gland Tumors
Status: Completed, Estimated PCD: 2008-09-29
Clinical trial
Dose-Intense Chemotherapy and Stem Cell Rescue in the Treatment of Inflammatory Breast Carcinoma
Status: Active (not recruiting), Estimated PCD: 2010-02-09
Clinical trial
Phase III Randomized Clinical Trial for Stage III Epithelial Ovarian Cancer Randomizing Between Primary Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy
Status: Recruiting, Estimated PCD: 2025-04-01
Clinical trial
A Phase I, Open-Label, Dose-Seeking Study of AZD2171 Given Daily Orally in Combination With Selected Standard Chemotherapy Regimens (CT) in Patients With Advanced Incurable Non-Small Cell Lung Cancer (NSCLC) or Colorectal Cancer
Status: Completed, Estimated PCD: 2007-09-18
Clinical trial
A Phase III Study of Standard Fractionation Radiotherapy With Concurrent High-Dose Cisplatin Versus Accelerated Fractionation Radiotherapy With Panitumumab in Patients With Locally Advanced Stage III and IV Squamous Cell Carcinoma of the Head and Neck
Status: Completed, Estimated PCD: 2015-05-16
Clinical trial
A Phase I and Pharmacokinetics Study of Docetaxel in Combination With Capecitabine and Cisplatin in Solid Tumors
Status: Completed, Estimated PCD: 2009-11-01
Clinical trial
A Phase III Trial of Concurrent Radiation and Chemotherapy for Advanced Head and Neck Carcinomas
Status: Completed, Estimated PCD: 2010-06-01
Clinical trial
A Randomized Phase II Trial of Paclitaxel-Carboplatin or Gemicitabine-Cisplatin in ECOG Performance Status 2 Non-Small Cell Lung Cancer Patients
Status: , Estimated PCD: 2005-01-01
Clinical trial
A Phase III Randomized Trial of Either M-VAC or Paclitaxel + Carboplatin as Postoperative Adjuvant Therapy in Patients With Muscle-Invasive Transitional Cell Carcinoma of the Bladder at High-Risk for Relapse
Status: Completed, Estimated PCD: 2001-08-01
Clinical trial
Randomized Phase II Study of Preoperative Combined Modality Paclitaxel / Cisplatin / RT or Irinotecan / Cisplatin / RT Followed by Postoperative Chemotherapy With the Same Agents in Operable Adenocarcinoma of the Esophagus
Status: Completed, Estimated PCD: 2009-09-01
Clinical trial
A Phase I-II Trial of MK-0646, a Monoclonal Antibody Against Insulin-Like Growth Factor-1 Receptor, in Combination With Etoposide and Cisplatin in Extensive Stage Small Cell Lung Cancer
Status: Completed, Estimated PCD: 2012-03-15
Clinical trial
Phase III Study Of Gemcitabine, Dexamethasone, And Cisplatin Compared To Dexamethasone, Cytarabine, And Cisplatin Plus/Minus Rituximab [(R)-GDP vs (R)-DHAP] As Salvage Chemotherapy For Patients With Relapsed Or Refractory Aggressive Histology Non-Hodgkin's Lymphoma Prior To Autologous Stem Cell Transplant And Followed By Maintenance Rituximab vs Observation
Status: Completed, Estimated PCD: 2013-07-29
Clinical trial
Phase III Trial of Methotrexate, Vinblastine, Doxorubicin and Cisplatin vs Carboplatin and Paclitaxel in Advanced Carcinoma of the Urothelium
Status: , Estimated PCD: 2005-09-01
Clinical trial
A Randomized Phase III Trial of Concurrent Biochemotherapy With Cisplatin, Vinblastine, Dacarbazine, IL-2 and Interferon A-2B Versus Cisplatin, Vinblastine, Dacarbazine Alone in Patients With Metastatic Malignant Melanoma
Status: , Estimated PCD: 2007-07-01
Clinical trial
A Randomized Phase II Study Of Gemcitabine Plus Radiotherapy Vs. Gemcitabine, 5-Fluorouracil And Cisplatin Followed By Radiotherapy And 5-Fluoraracil For Patients With Locally Advanced, Potentially Resectable Pancreatic Adenocarcinoma
Status: Completed, Estimated PCD: 2005-10-01
Clinical trial
Phase II Trial of Post-Operative Adjuvant Paclitaxel + Cisplatin in Patients With Adenocarcinoma of the Esophagus, Gastro-Esophageal Junction or Cardia
Status: , Estimated PCD: 2003-10-01
Clinical trial
A Phase II Trial of Preradiation Multiagent Chemotherapy for Adults With "Poor Risk" Medulloblastoma, PNET, and Disseminated Ependymoma
Status: , Estimated PCD: 2004-03-01
Clinical trial
Chemoembolization in Hepatocellular Carcinoma or Neuroendocrine Hepatic Metastases: A Phase II Multi-Center Trial
Status: Completed, Estimated PCD: 2011-05-01
Clinical trial
Randomized, Double Blind, Placebo Controlled Phase III Evaluation of Cisplatin + Placebo Versus Cisplatin + C225 a Mouse/Human Monoclonal Antibody to the Epidermal Growth Factor Receptor, in Patients With Metastatic and/or Recurrent Squamous Cell Cancer of the Head and Neck
Status: , Estimated PCD: 2004-09-01
Clinical trial
Multicenter Randomized Phase III Study Comparing Fixed Doses Versus Toxicity Adjusted Dosing of Cisplatin and Etoposide for Patients With Small Cell Lung Cancer.
Status: Active (not recruiting), Estimated PCD: 2023-12-01
Clinical trial
Phase III Comparison of Thoracic Radiotherapy Regimens in Patients With Limited Small Cell Lung Cancer Also Receiving Cisplatin and Etoposide
Status: , Estimated PCD: 2022-03-02
Clinical trial
Phase II Trial of Pembrolizumab in Combination With Trastuzumab, Fluoropyrimidine, and Platinum Chemotherapy in First Line Stage IV HER2-positive Metastatic Esophagogastric (EG) Cancer
Status: Completed, Estimated PCD: 2022-06-01
Clinical trial
A Phase 1b/2 Study With the Agonistic TRAIL-R1 Antibody, Mapatumumab, in Combination With Cisplatin and Radiotherapy as a First Line Therapy in Patients With Advanced Cervical Cancer.
Status: Completed, Estimated PCD: 2014-03-01
Clinical trial
Phase II Study of C225 (Erbitux or Cetuximab) in Combination With Cisplatin and Definitive Radiation in Unresectable Stage IV Squamous Cell Carcinoma of the Head and Neck
Status: Completed, Estimated PCD: 2009-07-01
Clinical trial
A Phase II Trial of Neoadjuvant Paclitaxel - Cisplatin Chemotherapy, Surgery and Adjuvant Radiation Therapy and 5-FU/Leucovorin for Gastric Cancer
Status: Completed, Estimated PCD: 2010-02-01
Clinical trial
Phase II Trial of Cetuximab Plus Cisplatin, 5- Fluorouracil and Radiation in Immunocompetent Patients With Anal Carcinoma
Status: Completed, Estimated PCD: 2015-11-01